Thermo Fisher Scientific Accelerates 100 Percent Renewable Electricity Goal for European Operations with New Solar Power Agreement with X-ELIO
Thermo Fisher Scientific (NYSE: TMO) has announced a 10-year virtual power purchasing agreement (VPPA) with X-ELIO for the Lorca solar project, expected to be operational in early 2026. The company's 73 MW portion will generate approximately 150,000 megawatt-hours of renewable electricity annually, equivalent to powering 40,500 European homes for a year.
This agreement, combined with the previously announced Serbal solar project, will enable TMO to match all its addressable European sites with 100% renewable electricity. The project advances the company's goal of achieving 80% global renewable electricity by 2030. The agreement includes a cohort of pharmaceutical partners (GSK, Gilead Sciences, and Haleon) through the Energize initiative, helping reduce both Scope 2 and Scope 3 emissions.
TMO serves as the cohort lead for this agreement, which aligns with its commitment to reach net-zero emissions by 2050 and its goal to reduce Scope 1 and 2 emissions by 50% by 2030 against a 2018 baseline.
Thermo Fisher Scientific (NYSE: TMO) ha annunciato un accordo di acquisto di energia virtuale (VPPA) della durata di 10 anni con X-ELIO per il progetto solare di Lorca, che dovrebbe entrare in funzione all'inizio del 2026. La porzione di 73 MW dell'azienda genererà circa 150.000 megawattora di elettricità rinnovabile all'anno, equivalente all'energia necessaria per alimentare 40.500 abitazioni europee per un anno.
Questo accordo, insieme al già annunciato progetto solare di Serbal, permetterà a TMO di abbinare tutti i suoi siti europei affrontabili con elettricità 100% rinnovabile. Il progetto sostiene l'obiettivo dell'azienda di raggiungere l'80% di elettricità rinnovabile a livello globale entro il 2030. L'accordo include un gruppo di partner farmaceutici (GSK, Gilead Sciences e Haleon) attraverso l'iniziativa Energize, contribuendo a ridurre sia le emissioni di Scopo 2 che di Scopo 3.
TMO funge da capofila di questo accordo, che si allinea con il suo impegno a raggiungere zero emissioni nette entro il 2050 e il suo obiettivo di ridurre le emissioni di Scopo 1 e 2 del 50% entro il 2030 rispetto a un livello di riferimento del 2018.
Thermo Fisher Scientific (NYSE: TMO) ha anunciado un acuerdo de compra de energía virtual (VPPA) por 10 años con X-ELIO para el proyecto solar de Lorca, que se espera esté operativo a principios de 2026. La parte de 73 MW de la compañía generará aproximadamente 150,000 megavatios-hora de electricidad renovable anualmente, suficiente para abastecer a 40,500 hogares europeos durante un año.
Este acuerdo, junto con el ya anunciado proyecto solar de Serbal, permitirá a TMO complementar todos sus sitios europeos abordables con electricidad 100% renovable. El proyecto respalda el objetivo de la compañía de alcanzar un 80% de electricidad renovable a nivel global para 2030. El acuerdo incluye un grupo de socios farmacéuticos (GSK, Gilead Sciences y Haleon) a través de la iniciativa Energize, ayudando a reducir tanto las emisiones del Alcance 2 como del Alcance 3.
TMO actúa como líder de este acuerdo, que está en línea con su compromiso de lograr cero emisiones netas para 2050 y su objetivo de reducir las emisiones de los Alcances 1 y 2 en un 50% para 2030 en comparación con un nivel de referencia de 2018.
Thermo Fisher Scientific (NYSE: TMO)는 X-ELIO와 함께 로르카 태양광 프로젝트에 대한 10년 가상 전력 구매 계약(VPPA)을 발표했습니다. 이 프로젝트는 2026년 초에 가동될 예정이며, 회사의 73 MW 분량은 연간 약 150,000 메가와트시의 재생 전기를 생산하여 40,500 유럽 가구에 연간 전력을 공급할 수 있습니다.
이 계약은 이전에 발표된 세르발 태양광 프로젝트와 결합되어, TMO가 모든 주소 가능한 유럽 사이트를 100% 재생 가능한 전기로 전환할 수 있도록 도와줄 것입니다. 이 프로젝트는 2030년까지 전 세계 재생 가능한 전력을 80% 달성하겠다는 회사의 목표를 진전시키는 것입니다. 이 계약에는 Energize 이니셔티브를 통해 제약 파트너(GSK, Gilead Sciences, Haleon)를 포함하여, Scope 2 및 Scope 3 배출량을 줄이는 데 기여하고 있습니다.
TMO는 이 계약의 리더 역할을 하며, 이는 2050년까지 탄소 중립 달성을 위한 의지와 2018년 기준에서 2030년까지 Scope 1 및 Scope 2 배출량을 50% 줄이겠다는 목표와 일치합니다.
Thermo Fisher Scientific (NYSE: TMO) a annoncé un contrat d'achat d'énergie virtuel (VPPA) de 10 ans avec X-ELIO pour le projet solaire de Lorca, qui devrait devenir opérationnel début 2026. La part de 73 MW de l'entreprise produira environ 150 000 mégawattheures d'électricité renouvelable par an, soit l'équivalent de l'alimentation de 40 500 foyers européens pendant un an.
Ce contrat, associé au projet solaire de Serbal déjà annoncé, permettra à TMO de faire correspondre tous ses sites européens concernés avec 100 % d'électricité renouvelable. Le projet fait progresser l'objectif de l'entreprise d'atteindre 80 % d'électricité renouvelable à l'échelle mondiale d'ici 2030. Le contrat inclut un groupe de partenaires pharmaceutiques (GSK, Gilead Sciences et Haleon) dans le cadre de l'initiative Energize, contribuant ainsi à réduire les émissions de Scope 2 et Scope 3.
TMO agit en tant que leader du groupe pour cet accord, qui est en adéquation avec son engagement à atteindre des émissions nettes nulles d'ici 2050 et son objectif de réduire les émissions de Scope 1 et 2 de 50 % d'ici 2030 par rapport à un niveau de référence de 2018.
Thermo Fisher Scientific (NYSE: TMO) hat einen 10-jährigen virtuellen Stromabnahmevertrag (VPPA) mit X-ELIO für das Solarprojekt in Lorca angekündigt, das voraussichtlich Anfang 2026 in Betrieb gehen wird. Der 73 MW-Anteil des Unternehmens wird jährlich etwa 150.000 Megawattstunden erneuerbare Energie erzeugen, was dem Strombedarf von 40.500 europäischen Haushalten für ein Jahr entspricht.
Dieser Vertrag, zusammen mit dem zuvor angekündigten Serbal-Solarprojekt, ermöglicht es TMO, alle adressierbaren europäischen Standorte mit 100 % erneuerbarem Strom zu versorgen. Das Projekt unterstützt das Ziel des Unternehmens, bis 2030 80 % der globalen erneuerbaren Energie zu erreichen. Der Vertrag umfasst eine Gruppe von pharmazeutischen Partnern (GSK, Gilead Sciences und Haleon) im Rahmen der Energize-Initiative, um sowohl Scope 2- als auch Scope 3-Emissionen zu reduzieren.
TMO fungiert als Leitunternehmen für diesen Vertrag, der mit seinem Engagement übereinstimmt, bis 2050 Netto-Null-Emissionen zu erreichen, sowie mit dem Ziel, die Scope 1- und 2-Emissionen bis 2030 um 50 % im Vergleich zu einem Basisjahr 2018 zu senken.
- Agreement will enable 100% renewable electricity for European operations
- Project advances company's goal of 80% global renewable electricity by 2030
- Strategic partnership reduces both Scope 2 and Scope 3 emissions
- Leadership position as cohort lead in industry sustainability initiative
- None.
Company leads value chain partners in purchase agreement that adds 118 megawatts (MW) of solar energy to enable decarbonization across the pharmaceutical and healthcare industries
Thermo Fisher’s share of Lorca solar, together with the Serbal solar project announced in December 2023, will match all of the company’s addressable European sites with 100 percent renewable electricity. The project also accelerates progress toward the company’s goal of achieving 80 percent global renewable electricity by 2030. Thermo Fisher’s 73 MW portion of the Lorca solar project will generate approximately 150,000 megawatt-hours of renewable electricity annually–equivalent to powering approximately 40,500 European homes for one year.1
The aggregated share of Lorca solar will simultaneously reduce Scope 2 and Scope 3 emissions for Thermo Fisher and the cohort of value chain partners—GSK, Gilead Sciences and Haleon—who participated in the agreement through the pharmaceutical and healthcare industries’ Energize initiative. Scope 2 emissions include those from purchased electricity to power a company’s facilities, while Scope 3 includes emissions from value chain partners.
“When we collaborate with our customers and suppliers, we accelerate our collective progress toward net-zero emissions,” said Konrad Bauer, senior vice president, global business services, Thermo Fisher Scientific. “Achieving 100 percent renewable electricity for our European sites is a significant milestone on our journey, and as cohort lead for this agreement facilitated by the Energize initiative, we are committed to leveraging our experience and insights to help enable similar milestones for our partners.”
The Energize initiative, managed by Schneider Electric together with the Pharmaceutical Supply Chain Initiative, is a collaborative partnership among the world’s leading pharmaceutical and healthcare companies and their suppliers that works to increase access to renewable electricity, drive supply chain decarbonization and accelerate action across the sector. Thermo Fisher joined Energize in 2021 to support its own renewable electricity adoption strategy, a key component of the company’s comprehensive net-zero strategy. Thermo Fisher was elected cohort lead for the Lorca solar VPPA, underscoring its industry leadership on the path to net zero emissions by 2050.
“Making the most out of our energy and resources is crucial as we collectively move toward more sustainable solutions across industries and around the world,” said John Powers, vice president, global renewables at Schneider Electric. “The Energize program aims to drive supply chain decarbonization across the pharmaceutical and healthcare industries while serving as a playbook for other sectors as they look to power their operations with renewable energy.”
Thermo Fisher established its global renewable electricity commitment in 2023, in alignment with the Sustainable Markets Initiative (SMI) Health Systems Task Force joint supplier standards. This followed the company’s raised commitment to reduce Scope 1 and 2 emissions by 50 percent by 2030 against a 2018 baseline, as well as its plans to power all of the company’s
For more information about Thermo Fisher’s environmental, social and governance progress, please visit www.thermofisher.com/csr.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over
1 From the Odysee-Mure project, based on the 2022 average electricity consumption per household in the European Union (EU) of approximately 3,700 kilowatt-hours (kWh) annually. The Odyssee-Mure project is coordinated by ADEME (Agency for Ecological Transition) with the technical support of Enerdata and Fraunhofer. It is supported by LIFE-CET program of the European Commission and is part of the activity of the European Energy Network (EnR) Club
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204112044/en/
Media Contact Information:
Sandy Pound
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Website: www.thermofisher.com
Investor Contact Information:
Rafael Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
Source: Thermo Fisher Scientific Inc.
FAQ
When will TMO's Lorca solar project become operational?
How much renewable electricity will TMO's portion of the Lorca project generate annually?
What are TMO's renewable electricity goals for Europe?
What is TMO's global renewable electricity target for 2030?
Which companies are partnering with TMO in the Lorca solar project?
